The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Resource: Utilizing DATATOP Biospecimens, 2011C-type Natriuretic Peptide (CNP): A Putative Biomarker of Neuronal Damage in Parkinson's Disease
Objective/Rationale:
CNP is a peptide produced by brain tissues where it acts to promote growth of nerve cells and their connections. Recent research in healthy humans has identified high... -
LRRK2, 2011fMRI of First Degree Relatives of LRRK2 Positive Parkinson's Disease Patients
Objective/Rationale:
First, to study the effect of the presence of the LRRK2 G2019S mutation on brain activation patterns in PD patients who recently converted into a diseased state by comparing... -
LRRK2, 2011Increased Sensitivity to the Loss of Nigrostriatal Dopamine Following Progressive MPTP Treatment in LRRK2 Mutant Small Models
Objective/Rationale:
It is known that a mutation of specific gene, called LRRK2, increases the risks of developing Parkinson’s disease in humans. The specific objective of this proposal is to... -
Target Validation, 2011Gene Delivery of MiRNAs to Reduce Alpha-synuclein: A New Therapy for PD
Objective/Rationale:
Alpha synuclein is a protein that in excessive amounts is implicated in Parkinson’s disease (PD). Alpha synuclein is also known to be the major constituent of a signature... -
MJFF Research Grant, 2011Generation of Alpha-synuclein Filament Protein and Characterization of Alpha-synuclein Rabbit Monoclonal Antibodies
Objective/Rationale:
Aggregation of alpha-synuclein plays a pivotal role in the development of Parkinson’s disease. This subproject focuses on supporting the MJFF initiative of generating monoclonal... -
MJFF Research Grant, 2011Screening & Identification of Small-molecule Pharmacophores Modulating LRRK2 Activity
Objective/Rationale:
Excessive activity of a human enzyme, named “LRRK2”, is closely associated with Parkinson’s Disease (PD). Small chemical compounds that inhibit this enzyme may be extremely...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.